Ying Yuan

17.5k total citations · 2 hit papers
378 papers, 10.8k citations indexed

About

Ying Yuan is a scholar working on Statistics and Probability, Management Science and Operations Research and Oncology. According to data from OpenAlex, Ying Yuan has authored 378 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Statistics and Probability, 84 papers in Management Science and Operations Research and 76 papers in Oncology. Recurrent topics in Ying Yuan's work include Statistical Methods in Clinical Trials (146 papers), Optimal Experimental Design Methods (81 papers) and Health Systems, Economic Evaluations, Quality of Life (45 papers). Ying Yuan is often cited by papers focused on Statistical Methods in Clinical Trials (146 papers), Optimal Experimental Design Methods (81 papers) and Health Systems, Economic Evaluations, Quality of Life (45 papers). Ying Yuan collaborates with scholars based in United States, China and Canada. Ying Yuan's co-authors include Guosheng Yin, Clifton E. Barry, David P. MacKinnon, Suyu Liu, David R. Sherman, Peter F. Thall, Ruitao Lin, Beibei Guo, J. Jack Lee and Richard Lee and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Ying Yuan

348 papers receiving 10.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

2000 796 citations Ying Yuan et al. profile →
Bayesian mediation analysis.

2009 469 citations Ying Yuan et al. profile →

Peers

Countries citing papers authored by Ying Yuan

Since Specialization

Citations

This map shows the geographic impact of Ying Yuan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Yuan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Yuan more than expected).

Fields of papers citing papers by Ying Yuan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Yuan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Yuan. The network helps show where Ying Yuan may publish in the future.

Co-authorship network of co-authors of Ying Yuan

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Yuan. A scholar is included among the top collaborators of Ying Yuan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Yuan. Ying Yuan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA84 Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC) 2025 ·Annals of Oncology ·Aiping Zhou, Zheng Li, Yihong Sun, (unknown), Heshui Wu, Lei Zhu, Hongliang Zong, Ying Yuan, (unknown), Liming Wu, Xiao Qu, (unknown), Yuting Wang, Hong Shen, (unknown), Shu Zheng, (unknown), Zhao Cui	0
2	COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies 2025 ·Statistics in Medicine ·Kai Chen, Kentaro Takeda, Ying Yuan	1
3	ELK4 ameliorates cognitive impairment and neuroinflammation induced by obstructive sleep apnea 2024 ·Brain Research Bulletin ·(unknown), Ying Yuan, Yang Ke, Ning Wang, (unknown)	3
4	A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies 2024 ·Statistical Methods in Medical Research ·(unknown), Ruitao Lin, Li Wang, Ying Yuan	0
5	Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing 2023 ·SHILAP Revista de lepidopterología ·(unknown), Molly S. Daniels, (unknown), Ecaterina E. Dumbrava, Ying Yuan, Keyur P. Patel, (unknown), (unknown), Chetna Wathoo, (unknown), (unknown), Wanlin Wang, Chacha Horombe, Milind Javle, Jordi Rodón, Timothy A. Yap, Banu Arun, Karen H. Lu, Funda Meric‐Bernstam	1
6	Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial 2023 ·Clinical Lung Cancer ·Caressa Hui, Eleanor Brown, (unknown), Millie Das, Heather A. Wakelee, Joel W. Neal, Kavitha Ramchandran, Nathaniel J. Myall, Daniel Pham, Lei Xing, (unknown), Nataliya Kovalchuk, Ying Yuan, Ying Lü, Michael Xiang, (unknown), Maximilian Diehn, Billy W. Loo, Lucas K. Vitzthum	1
7	Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer 2023 ·SHILAP Revista de lepidopterología ·Ji Son, Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp, Aung Naing, Shubham Pant, Sarina A. Piha‐Paul, Jordi Rodón, Vivek Subbiah, Apostolia M. Tsimberidou, Timothy A. Yap, Michael Frumovitz, Amir A. Jazaeri, Pedro T. Ramírez, Shannon N. Westin, Ying Yuan, Funda Meric‐Bernstam, David S. Hong	1
8	P11.84.A PHASE 1 TRIAL OF MARIZOMIB ALONE AND IN COMBINATION WITH PANOBINOSTAT IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) 2023 ·Neuro-Oncology ·(unknown), (unknown), Mark W. J. Strachan, (unknown), (unknown), Jayne Vogelzang, Keith L. Ligon, Sanda Alexandrescu, Patricia Baxter, Nicholas A. Vitanza, (unknown), (unknown), Ying Yuan, Wendy B. London, Michelle Monje	1
9	uTPI: A utility‐based toxicity probability interval design for phase I/II dose‐finding trials 2021 ·Statistics in Medicine ·(unknown), Jiguo Cao, Ying Yuan, Ruitao Lin	14
10	Healthy Moves to Improve Lifestyle Behaviors of Cancer Survivors and Their Spouses: Feasibility and Preliminary Results of Intervention Efficacy 2021 ·Nutrients ·Cindy L. Carmack, Nathan H. Parker, Wendy Demark‐Wahnefried, (unknown), George Baum, Ying Yuan, Sharon H. Giordano, Miguel A. Rodrı́guez-Bigas, Curtis A. Pettaway, Karen Basen‐Engquist	17
11	Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas 2019 ·Clinical Cancer Research ·Hong Jiang, (unknown), Teresa T. Nguyen, Juàn Fueyo, Xuejun Fan, Verlene Henry, Caroline C. Carrillo, (unknown), Marta M. Alonso, (unknown), Ying Yuan, Frederick F. Lang, Candelaria Gomez‐Manzano	32
12	A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies 2019 ·Statistics in Medicine ·Yanhong Zhou, J. Jack Lee, Ying Yuan	64
13	Accuracy, Safety, and Reliability of Novel Phase I Trial Designs 2018 ·Clinical Cancer Research ·Heng Zhou, Ying Yuan, Lei Nie	72
14	Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials 2018 ·Clinical Cancer Research ·Ying Yuan, Ruitao Lin, Daniel Li, Lei Nie, Katherine E. Warren	84
15	Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination 2017 ·Cancer Research ·Hong Jiang, Yisel Rivera-Molina, Candelaria Gomez‐Manzano, Karen Clise-Dwyer, Laura Bover, Luis M. Vence, Ying Yuan, Frederick F. Lang, Carlo Toniatti, Mohammad B. Hossain, Juàn Fueyo	161
16	Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials 2017 ·Clinical Cancer Research ·Fangrong Yan, Sumithra J. Mandrekar, Ying Yuan	108
17	Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters 2017 ·Clinical Cancer Research ·(unknown), Qian Zhang, Zhongyuan Chen, Han Liang, Gary B. Chisholm, Ying Yuan, Samuel C. Mok, Russell R. Broaddus, Karen H. Lu, Melinda S. Yates	92
18	Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials 2016 ·Clinical Cancer Research ·Ying Yuan, Kenneth R. Hess, Susan G. Hilsenbeck, Mark R. Gilbert	131
19	FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells 2015 ·Cancer Research ·(unknown), Ping Wei, Sicong Zhang, Jun Yao, Ying Yuan, Aidong Zhou, Frederick F. Lang, Amy B. Heimberger, Ganesh Rao, Suyun Huang	79
20	Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells 2011 ·Clinical Cancer Research ·Dimpy Koul, Jun Fu, Ruijun Shen, Tiffany A. LaFortune, Shuzhen Wang, Ningyi Tiao, Yong‐Wan Kim, Juinn-Lin Liu, (unknown), Ying Yuan, (unknown), Sauveur-Michel Maira, W.K. Alfred Yung	132

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact